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ABSTRACT
Gene fusion is one of the hallmarks of cancer. Recent advances in RNA-seq of 
cancer transcriptomes have facilitated the discovery of fusion transcripts. In this 
study, we report identification of a surprisingly large number of fusion transcripts, 
including six KANSARL (KANSL1-ARL17A) transcripts that resulted from the fusion 
between the KANSL1 and ARL17A genes using a RNA splicingcode model. Five of 
these six KANSARL fusion transcripts are novel. By systematic analysis of RNA-seq 
data of glioblastoma, prostate cancer, lung cancer, breast cancer, and lymphoma from 
different regions of the World, we have found that KANSARL fusion transcripts were 
rarely detected in the tumors of individuals from Asia or Africa. In contrast, they exist 
in 30 - 52% of the tumors from North Americans cancer patients. Analysis of CEPH/
Utah Pedigree 1463 has revealed that KANSARL is a familially-inherited fusion gene. 
Further analysis of RNA-seq datasets of the 1000 Genome Project has indicated that 
KANSARL fusion gene is specific to 28.9% of the population of European ancestry 
origin. In summary, we demonstrated that KANSARL is the first cancer predisposition 
fusion gene associated with genetic backgrounds of European ancestry origin.
INTRODUCTION
Genetic predisposition to cancer has been well known 
for several centuries initially through observation of unusual 
familial clusterings, and later through identification of cancer-
prone families that demonstrate Mendelian inheritance of 
cancer predisposition using different traditional techniques 
such as comparative genomic hybridization [1–4]. Over 100 
cancer predisposition genes (CPGs) have been identified, 
including BRCA1 and BRCA2 in breast cancer, TP53 in 
Li–Fraumeni syndrome, and APC in familial adenomatous 
polyposis [1]. All these CPGs are derived from known 
genes carrying point mutations; however, none of them 
are derived from gene fusion [1]. Since the genetic factors 
identified so far only explain a small percentage of familial 
cancer risks, discovery of novel genetic predisposition 
factors for cancer is needed [5]. Fusion transcripts, which 
can be derived from chromosomal rearrangements and 
RNA processing events such as cis- and trans-splicing [6], 
are of particular importance in that their products are able to 
elicit immune responses in cancers and other diseases and 
therefore may serve as cancer-specific antigens for cancer 
vaccine development [7–15], a field that is currently drawing 
extensive attention for cancer immunotherapy [7, 16–21].
Recent advances in RNA-seq have made it possible 
to systematically analyze human cancer transcriptomes 
for the discovery of fusion transcripts [10, 11, 22–25]. In 
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recent years, RNA-seq data have grown exponentially, and 
around 30,000 novel fusion transcripts and genes have been 
identified thus far [26, 27]. The key challenge of using RNA-
seq to identify fusion transcripts lies in mapping RNA-seq 
reads quickly and accurately to the reference genome [28]. 
Although enormous progress has been made and more than 30 
software and algorithms have been developed for this purpose, 
these systems are of low efficiency, sensitivity and accuracy 
although great efforts have been made to improve [6, 29–32]. 
For example, Kinsella et al. have developed them a method 
that allows to ambiguously map RNA-seq reads, and used it 
to identify KANSL1-ARL17A (KANSARL) fusion transcripts 
[33]. However, its fusion junction has turned out to be identical 
to a cDNA clone [34]. Additionally, details about this fusion 
that of transcript remain to be elusive, including its expression 
patterns, relationship to somatic and germline mutations, and 
association with cancer types and genetic backgrounds.
Both ARL17A and KANSL1 genes are located on 
the reverse strand of the chromosome 17q21.31. KANSL1 
encodes an evolutionarily-conserved nuclear protein, a 
subunit of MLL1 and NSL1 complexes that is involved 
in histone H4 acetylation and p53 Lys120 acetylation 
[35]. KANSL1 ensures faithful chromosome segregation 
during mitosis [36]. Two haplotypes of KANSL1 have been 
described; the H1 and the inverted H2 forms of 17q21.31 
polymorphism. Both contain independently derived, partial 
duplications of the KANSL1 gene. These duplications have 
recently arisen with high frequencies (26% and 19%) in the 
population of European ancestry origin [37]. Some KANSL1 
mutations have resulted in Koolen-de Vries syndrome 
(KdVS) (OMIM #610443), characterized by developmental 
delay, intellectual disability, hypotonia, epilepsy, 
characteristic facial features, and congenital malformations 
in multiple organs [38]. ARL17A gene encodes a protein 
of the ARF family that is involved in multiple regulatory 
pathways relevant to human carcinogenesis [39].
Previously, we have reported that recently gained 
human spliceosomal introns have a signature of identical 5’ 
and 3’ splice sites [40]. Based on this finding, we have found 
that both 5’ exonic sequences (E5) immediately upstream 
of introns and 3’ intronic sequences near the 3’ splice site 
(I3) are dynamically conserved among different lineages of 
eukaryotic introns. The conservation is reminiscent of self-
splicing group II introns and of constraints imposed by base 
pairing between intronic-binding sites (IBSs) and exonic-
binding sites (EBSs) [40]. Therefore, we propose that both 
E5 and I3 sequences constitute splicing codes, which are 
deciphered by as-yet-to-be characterized splicer proteins/
RNAs via base-pairing [40]. Using this splicingcode model, 
we developed a computational tool for analyzing RNA-seq 
datasets in order to study gene expression pattern, and to 
identify novel splicing isoforms and fusion transcripts.
In this study, we have used this software system 
to analyze RNA-seq data from a variety of cancer types, 
and identified over 1 million fusion transcripts of unique 
splice junctions. To verify the reliability and robustness 
of our approach, we selected KANSARL fusion transcripts 
for systematic validation and characterization. We have 
found that KANSARL fusion transcripts are associated 
with multiple types of cancer. We have further shown that 
KANSARL represents the first predisposition fusion gene 
specific to the population of European ancestry origin.
RESULTS
Development of a computational high 
throughput tool, SCIF (SplicingCodes Identify 
Fusion Transcripts), for identification of fusion 
transcripts
To develop an improved computational program 
for identification of fusion transcripts, we first generated 
a human splicingcode table as described previously [40, 
41]. Supplementary Figure 1 shows the flowchart of using 
the human splicingcode to identify fusion transcripts from 
human RNA-seq data. After removal of highly-repetitive 
sequences, poor quality sequences, and duplicated 
sequences, we reduced our collection of introns from 
382,279 to 230,000, the majority of which are unique. To 
identify fusion transcripts, we selected 20-bp sequences 
as key length, and screened our 230,000 pairs of 5’ and 3’ 
exonic keys. To improve the alignment accuracy and speed, 
we have added an important step to continue sequence 
alignments, that is, the sequences upstream of the 5’ key and 
downstream of the 3’ key of the RNA-seq read were further 
aligned to the corresponding genomic region of 5’ and 3’ 
exons. Supplementary Figure 2 shows that the 5’ region 
of an RNA-seq read is identical to the 5’ exonic key from 
Gene A, and its immediately downstream sequences were 
aligned to the 3’ exonic key of Gene B. If both remaining 
regions are identical to the corresponding genomic regions, 
this read was then blasted against AceView human mRNAs/
EST database and the human gene database containing 20-
kb upstream sequences of 5’ genes and 20-kb downstream 
sequences of 3’ genes, to remove sequences from 
pseudogenes, gene duplications and alternatively-spliced 
sequences. If blasted results confirmed that the RNA-seq 
read was originated from two different regions or genes, 
this read was deemed as a fusion transcript. To minimize 
potential errors, we randomly generated exon-exon and 
exon-intron chimeric sequence datasets to check artificial 
exon-exon and exon-intron chimeric sequences. We 
analyzed over 20,000 million of 75-101 bp RNA-seq reads, 
and did not find a single copy of such random chimeric 
sequences, suggesting that the artifacts generated during the 
experiments have been reduced to close to zero. Because our 
system requires that both 5’ and 3’ keys of fusion transcripts 
are in the splicingcode table and their remaining sequences 
are identical to the corresponding genomic sequences of the 
keys, this approach allows us to remove poor-quality and 
repetitive reads quickly and to have a very fast speed in 
aligning the entire reads to their genomic targets with much 
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higher accuracy. Consequently, based on the lengths of 
identical sequences, we found that the maximum of random 
error to generate a fusion transcript was 1.2 × 10-24 and the 
medium error was 1 × 10-59. We have named this program 
SCIF (SplicingCodes Identify Fusion Transcripts).
Identification of KANSARL fusion transcripts
We first used the above approach to analyze 
37,208 millions of RNA-seq reads from 39 cancer 
cell lines (designated as ECD39), majorities of which 
were downloaded from the ENCODE project [42]. We 
identified a total of 92,817 fusion transcripts with unique 
fusion junctions. We then selected KANSARL fusion 
transcripts for further investigation. The existence and 
abundances of multiple KANSARL isoforms in cells ruled 
out the possibility that KANSARL fusion transcripts are 
trans-spliced products. The ARL17A and KANSL1 genes 
consist of 11 and 16 exons, respectively (Figure 1A). An 
inverted genomic structure of KANSL1→ARL17A gene 
order to generate KANSARL fusion transcripts results 
from putative inversions or duplications of the normal 
Figure 1: Identification and characterization of KANSARL (KANSL1-ARL17A) fusion transcripts. (A) A schematic 
diagram showing steps of genetic rearrangements from normal genomic structures of ARL17A → KANSL1 genes to inverted genomic 
structures of KANSL1 → ARL17A genes on the chromosomal band 17q21.31. Dashed white horizontal arrow and solid white vertical 
arrow represent genomic rearrangements and potential fusion gene structures. Solid red and black horizontal arrows indicate ARL17A and 
KANSL1 genes, respectively. Solid blue arrows represent LRRC37A and MAPT genes, respectively. The dashed horizontal black arrow 
indicates undetermined genomic regions. Black and black squares represent KANSL1 and ARL17A exons respectively. (B) The schematic 
diagram shows KANSARL fusion transcripts identified so far. Black and red squares represent KANSL1 and ARL17A exons respectively. 
Dashed lines indicate omitted regions. The numbers above the black and red squares are exon numbers. The numbers within sequences 
indicate omitted numbers of nucleotides; (C) Validation of KANSARL isoform 1 in A549, HeLa, K562, 786-O and OS-RC-2 cell lines; (D) 
Validation of KANSARL isoform 2 in A549, HeLa, K562, 786-O and OS-RC-2 cell lines; (E) Detection of KANSL1 gene expression in 
A549, HeLa, K562, 786-O and OS-RC-2 cell lines; (F) Detection of ARL17A gene expression in A549, HeLa, K562, 786-O and OS-RC-2 
cell lines; (G) Detection of GAPDH gene expression as loading controls in A549, HeLa, K562, 786-O and OS-RC-2; (H) Sanger sequencing 
validation of KANSARL isoform 2. The black and red letters represent KANSL1 exon 3 and ARL17A exon 3 sequences, respectively. And 
(I) Sanger sequencing validation of KANSARL genomic breakpoint in the Hela-3 cell line. The black and red letters indicate KANSL1 
and ARL17A intronic sequences, respectively. Vertical arrows indicate the fusion junctions. The black and red lines indicate KANSL1 and 
ARL17A sequences, respectively. All markers are 100 bp DNA markers.
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genomic structure, ARL17A→ KANSL1 (Figure 1A). 
Figure 1B and Supplementary Table 1 show that the six 
KANSARL isoforms 1 to 6 identified in ECD39 datasets. 
In these six KANSARL isoforms, KANSL1 gene uses three 
splice junctions of exons 2, 3, and 6, indicating that the 
5’ breakpoint occurred at least downstream of the exon 
2. ARL17A retains exons 3, 4, 7, and 8, indicating that 
the 3’ breakpoint occurred upstream of the ARL17A exon 
3 (Figure 1B). It is notable that only KANSARL isoform 
2 among these six KANSARL isoforms was identified 
previously [33, 34], and the other five isoforms are novel. 
Supplementary Figure 3 shows that the six KANSARL 
fusion transcripts encode putative peptides with 437, 
483, 496, 505, 450, and 637 amino acids, respectively. 
The majority of these peptide sequences were derived 
from KANSL1 gene. Thus, these putative KANSARL 
fusion peptides are similar to those derived from KANSL1 
truncated mutants and retain only coiled-coil domain, 
while lost the WDR5 binding region, Zn finger, the 
domain for KAT8 activity, and PEHE [38].
Experimental validation of KANSARL fusion 
transcripts and genomic breakpoint
We next aimed to validate KANSARL fusion 
transcripts shown in Figure 1B. To this end, we used 
A549, HeLa, and K562 cells, which are positive for 
KANSARL fusion transcripts in RNA-seq datasets 
(Supplementary Table 2), for RT-PCR and sequencing 
analyses, and cell lines 786-O and OS-RC-2 were used 
as negative controls. Figure 1C shows that amplification 
of A549, HeLa, and K562 cDNAs using the primer pair 
KANSARLISOF1 and KANSARLISOR1 generated PCR 
fragments with the expected size 379-bp (Supplementary 
Table 4). Direct Sanger DNA sequencing of the cloned 
PCR fragments confirmed that they have the correct fusion 
junction of KANSARL fusion isoform 1 (Supplementary 
Figure 4). Figure 1D shows that PCR using the primer 
pairs KANSARLF1 and KANSARLR1 (Supplementary 
Table 4) produced fragments with the expected size 
431-bp. Sequencing analysis shows that these fragments 
contain the expected fusion junction of KANSARL isoform 
2 (Figure 1H), which was reported previously [33, 34]. 
Overall, we have shown that both KANSARL isoforms 1 
and 2 contain the correct fusion junction sequences.
To better understand KANSARL fusion events, we 
performed RT-PCR analysis for KANSL1 and ARL17A 
expression using primers overlapping breakpoints of 
KANSL1 and ARL17A genes (Supplementary Table 4) 
in KANSARL-positive (A564, HeLa, and K562) and 
KANSARL-negative (786-O and OS-RC-2) cell lines. 
Figure 1E&1F show that the expression patterns of 
KANSL1 and ARL17A genes in A564, HeLa, and K562 
are very similar to those in 786-O and OS-RC-2. Figure 
1G shows the expression levels of GAPDH gene that 
were used as loading controls.
To further validate the KANSARL genomic 
breakpoint, we have also performed analysis of whole 
genome shotgun (WGS) data from KANSARL-positive 
individuals of CEPH/Utah Pedigree 1463 and results 
indicated that the genomic breakpoints are located at 
KANSL1 intron 3 and ARL17A intron 2 (Supplementary 
Figure 5). Then, we have isolated genomic DNA from Hela-
3 cells and performed genomic amplification using the 
primers gKANSL1F1 and gARL17AR1 (Supplementary 
Table 4). Supplementary Figure 6 shows the PCR product, 
which was then recovered for direct DNA sequencing 
(Supplementary Figure 7). DNA analysis and manual 
inspection have located the breakpoint of KANSL1 intron 
3 and ARL17A intron 2 (Figure 1I), and indicated that the 
PCR product contains the identical genomic breakpoint 
sequences of the H1 form of the 17q21.31 inversion 
polymorphism reported previously [43]. Thus, we 
have validated the KANSARL fusion breakpoint at both 
RNA and genome levels and derived from the 17q21.31 
inversion polymorphism reported previously [43].
Characterization of the expression patterns of 
KANSARL fusion transcripts in ECD39 cancer 
cell lines
As shown in Supplementary Table 2, 11 out of 
39 (29%) cancer cell lines express KANSARL fusion 
transcripts, suggesting that KANSARL is a highly-recurrent 
fusion gene. To verify this claim, we performed RT-PCR 
analysis for a pool of uncharacterized breast cancer and 
lymphoma cell lines. Figure 2A shows that among 10 
breast cancer cell lines, HCC-1937, T47D, MAD-436, and 
SUM-157 cells express KANSARL isoform 2. Figure 2B 
shows that among the eight lymphoma cell lines, DHL-
5, DHL-8, OCI-Ly10, and Val express KANSARL isoform 
2. Figure 2C&2D show that all the eight lymphoma 
cell lines have at least one copy of KANSL1 gene and 
one copy of ARL17A gene. Thus, the results show that 
KANSARL fusion transcripts exist in cancer cell lines at 
high frequencies.
To further investigate the differential expression 
of these six individual KANSARL isoforms in cancer cell 
lines, we analyzed their relative abundance of in ECD39 
dataset [42]. Figure 3A and Supplementary Table 1 
show the distribution of raw counts of the six KANSARL 
fusion transcripts, among which KANSARL isoform 2 is 
the most abundant, and is 50-fold and 1,216-fold greater 
than isoforms 1 and 3, respectively. Supplementary Table 
2 shows that KANSARL fusion transcripts were detected 
in 11 out of 39 cancer cell lines, including A375, A549, 
G401, H4, HeLa-3, HT29, K562, Karpas422, M059J, OCI-
Ly7, and SK-N-DZ. In contrast, we have not identified a 
single copy of KANSARL fusion transcript in the rest of 
28 cell lines, among which HepG2 has the largest number 
(over 1,200 million) of RNA-seq reads analyzed so far, 
suggesting that the depths of RNA-seq reads have no 
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impacts on our analysis outcomes. To normalize for a total 
number of reads, we adjusted our values relative to the 
number of splice junctions per million reads (NSJMR). We 
found that all the 11 cell lines express KANSARL isoform 
2 (Figure 3B), and different expression levels of the other 
five isoforms. Karapas-422, A549, H4, HT29, A375, SK-
N-SH, and K562 cells are among the cancer cell lines with 
the highest levels of KANSARL fusion transcripts, and are 
more than 7-fold on average than the other four cell lines.
Quantitative real-time PCR results indicate that 
KANSARL isoform 2 is expressed at 0.36%, 0.28% 
and 1.28% of the GAPDH expression levels in A549, 
HeLa, and K562, respectively, while KANSARL isoform 
1 is expressed only at 0.0056%, 0.0037% and 0.015% 
of the GAPDH expression levels in the same cell 
lines (Supplementary Table 3). Figure 3C shows that 
KANSARL isoform 2 is expressed at 64 to 83 fold higher 
than KANSARL isoform 1. The differential expression 
patterns between these two KANSARL isoforms detected 
using real-time PCR are generally consistent with that 
obtained from RNA-seq data analysis (Supplementary 
Table 1).
Figure 2: RNA-typing of KANSARL fusion transcripts in breast and lymphoma cancer cell lines. Detections of KANSARL 
transcripts were evaluated by RT-PCR with the primers shown in Supplementary Table 4. (A) breast cancer cell lines; (B) lymphoma cell 
lines. (C) Detection of KANSL1 gene expression; (D) Detection of ARL17A gene expression; and (E) Detection of GAPHD gene expression 
as controls. All markers are 100bp DNA markers;
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KANSARL fusion transcripts are expressed 
predominantly in cancer patients with European 
ancestry origin
Since Supplementary Table 2 shows that KANSARL 
fusion transcripts are expressed in brain cancer cell lines 
including H4, MJ059 and SK-N-DZ, we were prompted 
to identify and characterize KANSARL fusion transcripts in 
glioblastomas. To this end, we analyzed the glioblastoma 
RNA-seq dataset from Columbia University Medical Center, 
New York (designated as CGD), which has a total of 94 
samples from 27 glioblastoma patients and 17 non-neoplastic 
brain tissues [44]. Figure 4A and Supplementary Table 5 show 
that 14 of the 27 (51.9%) GBM patients express KANSARL 
fusion transcripts. In contrast, KANSARL fusion transcripts 
were detected only in 2 out of 17 (or 11.8%) non-neoplastic 
brain tissues. The difference in the expression frequencies of 
KANSARL fusion transcripts between glioblastomas and non-
neoplastic persons is statistically significant (Supplementary 
Table 5, Fisher’s exact test, p<0.01; Figure 4A), indicating 
that KANSARL fusion transcripts are preferentially associated 
with diffuse glioblastomas.
Figure 3: Characterization of KANSARL isoform expression in ECD39 cell lines, A549, HeLa and K562. (A) Distribution 
of raw counts of the six KANSARL isoforms identified in the ECD39 datasets; (B) Normalization of raw counts into NSJMR (Numbers of 
Splice Junctions per Million) of KANSARL fusion transcripts among the KANSARL-positive cancer cell lines. Y-axis shows Numbers of 
Splice Junctions per Million Reads (NSJMR). (C) Quantification of KANSARL isoform 1 and 2 of A549, HeLa and K562 by real-time PCR 
with the primers shown in Supplementary Table 4. The raw real-time RT-PCR data of KANSARL isoform 1 and 2 of A549, HeLa and K562 
are listed in Supplementary Table 3.
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To further investigate KANSARL fusion transcripts 
in glioblastomas, we performed a comparative expression 
analysis of the glioblastomas dataset deposited by Beijing 
Neurosurgical Institute, Beijing, China (designated as 
BGD), which has 272 gliomas of different clinic prognosis 
stages [45]. Surprisingly, only two out of the 272 BGD 
glioblastoma samples (less than 1%) are KANSARL 
positive (Figure 4B). Thus, KANSARL positivity in BGD 
glioblastoma is 70 fold lower than that in the CGD dataset. 
Supplementary Table 6 shows that the difference between 
CGD and BGD is statistically significant (Fisher’s exact 
test, p<0.001).
The dramatic difference in the expression 
frequencies of KANSARL fusion between the CGD and 
BGD datasets has raised the possibility that KANSARL 
fusion transcripts are associated with cancer patients 
of European ancestry origin. To confirm this claim, we 
performed comparative analyses of RNA-seq datasets 
in more types of cancers, including prostate cancer, 
breast cancer, lung cancer and lymphoma from different 
geological regions of the World (see detailed analysis in 
Supporting Data). Our results show that KANSARL fusion 
transcripts were rarely found in the tumor samples from 
Asia and Africa, but were detected in 30~52% of cancer 
samples from patients in North America. Therefore, 
we conclude that KANSARL fusion transcripts are 
preferentially associated with tumor samples from patients 
with European ancestry origin.
Figure 4: Systematic analyses of KANSARL fusion transcripts in glioblastomas. (A) Analysis of KANSARL fusion transcripts 
in the CGD glioblastoma RNA-seq datasets. “Normal” and “Gliomas” represented brain tissues of non-neoplastic donors and diffuse 
glioblastomas (GBM) patients, respectively. (B) Comparative analysis of KANSARL fusion transcripts between the BGD and CGD 
datasets that consist of 272 glioblastoma patients from Beijing Neurosurgical Institute, Beijing, China, and 27 glioblastoma patients of 
Columbia University Medical Center, New York, USA, respectively. Comparative analyses of prostate cancer, lung cancer, breast cancer 
and lymphomas from different geological regions of the World are shown in Supporting Materials.
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KANSARL fusion transcripts are associated 
with prostate cancer biomarker TMPRSS2-ERG 
fusion transcripts in prostate cancer
In supporting data, analysis of 25 high-risk prostate 
tumors from Vancouver Prostate Center, Vancouver, 
Canada (VPD) [46] has shown that 13 of them (52%) 
have KANSARL fusion transcripts. We have also found 
that KANSARL and TMPRSS2-ERG are the two most 
highly-expressed fusion genes in the VPD prostate 
cancer dataset. These observations suggest a possible 
relationship between KANSARL fusion transcripts and 
somatic TMPRSS2-ERG fusion transcripts. We have 
further shown that TMPRSS2-ERG fusion transcripts 
are expressed in 15 out of 25 prostate tumors, consistent 
with the notion that TMPRSS2-ERG fusion transcripts 
are prostate cancer biomarkers [46]. Figure 5 and 
Supplementary Table 7 show that 13 out of 15 TMPRSS2-
ERG-positive prostate tumors are KANSARL-positive, and 
100% KANSARL-positive prostate tumors express somatic 
TMPRSS2-ERG fusion transcripts. In contrast, only two 
TMPRSS2-ERG-positive prostate tumors were detected 
in 12 KANSARL-negative prostate tumors. The difference 
of TMPRSS2-ERG fusion transcripts between KANSARL-
positive and KANSARL-negative tumors is significant 
(Supplementary Table 7, Fisher’s exact test, p<0.001), 
indicating that KANSARL fusion transcripts are associated 
with prostate cancer biomarker TMPRSS2-ERG fusion 
transcripts in the VPD tumor patients.
Furthermore, Supplementary Table 8 shows that 
the prostate and breast cancers with KANSARL fusion 
transcripts have increased the numbers of recurrent read-
through (epigenetic) fusion transcripts than those without 
KANSARL fusion transcripts, suggesting that KANSARL 
fusion transcripts may be involved in epigenetic 
alternations in early stages of cancer development.
KANSARL fusion gene is familially inherited and 
may be ubiquitously expressed in KANSARL-
bearing individuals
The presence of KANSARL fusion transcripts in 
normal and adjacent tissues in CGD and VPD raised the 
possibility that KANSARL fusion transcripts are derived 
from a germline-inherited fusion gene. To investigate this 
possibility, we performed RNA-seq data analysis for the 
lymphoblastoid cell lines derived from the families in the 
CEU population (CEPH/Utah Pedigree 1463, Utah residents 
with ancestry from northern and western Europe), which 
includes a three-generation family with 17 individuals 
[47]. Supplementary Table 9  and Supplementary Figure 8 
show that KANSARL fusion transcripts were detected in 15 
of 17 family members, as indicated by black squares and 
circles in Supplementary Figure 8, except son (NA12885), 
which is deviated from the first Mendel law. A reasonable 
explanation is that the grandfather sample (NA12889) 
might have been mixed with the son sample (NA12885). 
To prove this possibility, we performed analyses of 
the WSG data (PRJEB3381) and RNA-seq from 1000 
Genome Project, and shown that both WSG and RNA-seq 
of grandfather sample (NA12889) are KANSARL-negative 
while WGS of the son (NA12885) is KANSARL-positive 
(Supplementary Table 10). Supplementary Table 10 
shows the genomic breakpoint 1 and 2 of the KANSARL 
fusion gene (Supplementary Figure 5 and 9) identified by 
analysis of WGS data among some members of CEPH/
Figure 5: Relationship between KANSARL fusion transcripts and somatic TMPRSS2-ERG fusion transcripts in VPD 
prostate tumors. The dataset VPD has 25 prostate patient samples from Vancouver Prostate Centre [46]. KANSARL+ and KANSARL- 
represented KANSARL-positive and KANSARL-negative tumor samples, respectively. TMPRSS2-ERG fusion gene is the predominant 
molecular subtype of prostate cancer.
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Utah Pedigree 1463. Therefore, Both WGS and RNA-
seq data support that the father (NA12877) and the 
mother (NA12878) have the genotypes of KANSARL-
/KANSARL- and KANSARL+/KANSARL+ respectively and 
all their offsprings are the genotype KANSARL+/KANSARL- 
(Figure 6A).
As shown above, KANSARL is a familially-
inherited fusion gene. A critical question was then whether 
KANSARL fusion transcripts exist in general populations. 
To answer this question, we analyzed RNA-seq data of 
the lymphoblastoid cell lines of the 1000 Genome Project 
[48]. Supplementary Table 11 shows that no single copy 
of KANSARL fusion transcripts has been detected in the 
Nigeria YRI (Yoruba in Ibadan) population. In contrast, 
Figure 6B and Supplementary Table 11 show that 
KANSARL fusion transcripts have been found in 33.7% 
GBR (British from England and Scotland), 26.3% FIN 
(Finnish in Finland) and 26.9% TSI (Toscani in Italia) 
populations, respectively. The differences of KANSARL 
frequencies among the GBR, FIN, and TSI population are 
Figure 6: Inheritance and distribution of KANSARL fusion transcripts in the population of European ancestry origin. 
(A) Diagrams of correct KANSARL inheritance in the CEPH/Utah Pedigree 1463, which includes four grandparents, two parents, and eleven 
children. Black and white squares represent KANSARL-positive and KANSARL-negative males while black and white squares indicate 
KANSARL-positive and KANSARL-negative females. The black lines represent relationships among the family members. The diagram is 
drawn based on RNAs-seq and WGS data. (B) Analysis of KANSARL fusion transcripts in the RNA-seq data of the lymphoblastoid cell 
lines of the 1000 Genome Project [48]. The diagram shows frequencies of KANSARL fusion transcripts in some populations of European 
and African ancestries. GBR is British from England and Scotland; FIN indicates Finnish in Finland; TSI represents Toscani in Italia, and 
YRI is Yoruba in Ibadan, Nigeria.
Oncotarget50603www.impactjournals.com/oncotarget
not statistically significant (data not shown), suggesting 
that these differences may be caused by sampling errors. 
However, their differences with that of Nigeria YRI 
are statistically significant (Supplementary Table 11, 
Fisher’s exact test, p<0.001), confirming our claim that 
KANSARL fusion transcripts are specific to the population 
of European ancestry origin.
As Supplementary Table 2 shows, KANSARL fusion 
transcripts are expressed in many tissues and organs 
in KANSARL-bearing individuals. To systematically 
understand the patterns of KANSARL gene expression 
in human tissues, we analyzed RNA-seq datasets from 
Science for Life Laboratory, Sweden (designated as 
SSTD), which are originated from 32 different tissue 
samples of 127 healthy individuals [49]. Supplementary 
Table 12 shows that KANSARL fusion transcripts are 
detected in 28 of 32 tissues analyzed, except bone 
marrow, kidney, stomach and smooth muscle. These data 
suggest that KANSARL fusion transcripts are ubiquitously 
expressed in the tissues and organs of KANSARL-bearing 
individuals.
DISCUSSION
In this study, we have developed and used our high 
throughput computational system SCIF to systematically 
analyze KANSARL fusion transcripts in a variety of 
cancer and normal samples with high capacity, high 
sensitivity, high accuracy and much lower computation 
time consumption. Our results demonstrate that KANSARL 
fusion transcripts are derived from a cancer predisposition 
fusion gene specific to the population of European 
ancestry origin.
Technical improvements for profiling fusion 
transcripts from RNA-seq datasets
Chimeric RNAs are well known to be generated 
from chromosomal rearrangements, including 
translocations, deletions, and inversions. Recently, trans-
splicing and cis-splicing of read-through pre-mRNAs 
between adjacent genes have been shown as emerging 
mechanisms for their generation [6]. Intergenically spliced 
fusion transcripts, which could be present at low levels in 
a given cancer type, represent a new repertoire of cancer-
specific biomarkers for early cancer detection, and also 
have potential applications in cancer diagnosis, prognosis, 
and therapeutic design [6, 28].
The major obstacles to analyze RNA-seq data--“Big 
Data” are to map reads to the genome with high efficiency 
and accuracy. As shown in Supplementary Figure 1, to 
improve accuracy and efficiency, first, SCIF has directly 
mapped raw sequences of RNA-seq reads to the human 
genomes instead of clustering. Secondly, SCIF has directly 
extended their flanking sequence alignments after partial 
sequences of a read were mapped to two different genes, 
as shown in Supplementary Figure 2. A desktop computer 
with a core of i5 and 8 GB memory can process 25~120 
millions of RNA-seq reads per hour since validation times 
used by BLAST constitute up to 80% of the computation 
costs and are highly variable. The SCIF software can 
detect a single copy of a given fusion transcript to over 
10,000 fusion transcripts per sample.
In our practice, to generate consistent KANSARL 
data, we have set the minimum 20 million RNA-seq 
reads for KANSARL analysis. These quality controls have 
greatly increased data reproducibility and minimized 
misalignment errors to false positivity less than 1%. For 
example, the CGD 27 glioblastoma dataset includes 39 
CE samples and 36 NE sequencing samples that were 
effectively constituted as multiple duplicate experiments 
in the context of KANSARL fusion transcripts [44]. 
All KANSARL-positive samples were detected in the 
corresponding CE and NE samples and the duplicate 
samples, and all KANSARL-negative samples are also 
reproducible in analysis results. That is, analysis results of 
100% of both KANSARL-positive and KANSARL-negative 
samples can be reproducible, indicating that our approach 
is reliable.
Moreover, analysis of the VPD prostate cancer 
RNA-seq dataset using SCIF has identified 16 TMPRSS2-
ERG fusion transcripts (rearrangements), 11 of which are 
novel (manuscript in preparation). Thus, our technology 
overcomes the major challenges and limitations in 
previous techniques, and provides a powerful tool for 
detection of low-level fusion transcripts that can serve as 
biomarkers for early cancer diagnosis [6].
KANSARL fusion gene is associated with 
polymorphism of the chromosomal band 17q21.31
The identical fusion junction of KANSARL fusion 
transcripts and genomic breakpoint of the KANSARL fusion 
gene (Figure 1H and Supplementary Figure 7) with those 
from the H1 form of 17q21.31 inversion polymorphism 
suggest that KANSARL fusion transcripts are derived 
from the H1 form of 17q21.31 inversion polymorphism, 
which counts for 26% population of European ancestry 
origin [43]. Since we have excluded the data from Utah 
residents with ancestry from northern and Western Europe 
like those of CEPH/Utah Pedigree 1463, average 28.9% 
KANSARL fusion transcripts in population of European 
ancestry origin are much higher than 26% of the H1 form 
[43]. One of possibilities is that complexities of duplications 
make it difficult to perform accurate analysis of WGS data 
and result in lower numbers of the H1 form. The second 
possibility is that additional genomic breakpoints exist 
in the chromosomal band 17q21.31. The presence of the 
putative genomic breakpoint 2 of KANSARL fusion gene 
in the CEPH/Utah Pedigree 1463 supports this possibility 
(Supplementary Figure 9 and Supplementary Table 10). 
However, the additional KANSARL genomic breakpoint 
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will be required for further confirmation. This uncertainty 
of the putative KANSARL fusion genomic breakpoints 
suggests that RNA-typing of KANSARL fusion transcripts 
will provide more accurate data than DNA-typing of the 
KANSARL genomic breakpoints.
KANSARL as the first cancer predisposition 
fusion gene that may play crucial roles in 
tumorigenesis
We have provided solid evidence, for the first 
time, supporting that the KANSARL fusion transcripts 
are associated with multiple types of cancer, including 
glioblastomas, prostate, breast cancer, lung cancer and 
lymphomas. KANSARL fusion transcripts have been 
detected in healthy individuals of European ancestry 
origin and are familially-inherited. These results support 
our claim that KANSARL is a cancer predisposition fusion 
gene specific to populations of European ancestry origin.
In all analyzed datasets, we have detected KANSARL 
fusion transcripts in all samples with KANSARL fusion gene, 
and the isoforms 1 and 2 have significantly higher expression 
levels in cancer patients compared to healthy individuals in 
general. However, isoforms 3-6 are expressed at very low 
levels and their differences cannot be determined.
All the six putative fusion peptides encoded by 
KANSARL fusion transcripts lack some functional 
domains, and therefore cancer patients expressing 
KANSARL fusion transcripts would display reduced 
activities of the histone acetyltransferase KAT8 and 
p53 [50–52]. It is quite possible that the reduction of 
KAT8 and p53 activities results in hypermutations in 
certain chromosomal regions of cancer cells and/or 
epigenetic changes that generate new read-through fusion 
transcripts, as shown in Supplementary Table 8. Since 
KANSARL-bearing cancer patients may be not sensitive 
to histone deacetylase inhibitors (HDACis) due to lower 
histone acetylation, KANSARL-negative patients may be 
respond well to treatments of HDACis.
In summary, our results demonstrate that KANSARL 
fusion gene exists in many types of cancer and is the 
first novel germline fusion gene specific to the genetic 
backgrounds of European ancestry origin. Our research 
provides an example to use our SCIF system for discovery of 
novel fusion transcripts that may play underappreciated but 
crucial roles in tumorigenesis and have promising therapeutic 
applications by serving as cancer biomarkers, drug targets, or 
specific epitopes for cancer vaccine development.
MATERIALS AND METHODS
Isolation of total RNAs from cell lines
Medium was removed from100-mm culture dishes 
and 1 ml of Trizol reagent (Invitrogen, CA) was added 
directly in each 100-mm culture dish. The cells were lysed 
by vortex vigorously for 15 seconds and the mixes were 
incubated at room temperature for 2-3 min. The samples 
were then centrifuged at 4,000 g for 15 min to separate 
the mixtures into a lower red, phenol-chloroform phase 
and a colorless upper aqueous phase. RNA in the aqueous 
phase was precipitated by mixing with 0.5 volumes of 
isopropyl alcohol for 10 min, and then centrifuging at 
12,000 g for 10 min at room temperature. The RNA pellet 
was washed twice with 1 ml of 75% ethanol, air-dried, and 
then dissolved in 40-80 μl of RNase-free H2O. The organic 
phase was saved for isolation of DNA or protein.
cDNA synthesis
The first-strand cDNA synthesis was carried out 
using oligo(T)15 and/or random hexamers using TaqMan 
Reverse Transcription Reagents (Applied Biosystems Inc., 
Foster City, CA, USA) as suggested by the manufacturer. 
In brief, to prepare 2× RT master mix, we pooled 10 μl 
of reaction mixes containing final concentrations of 1X 
RT Buffer, 1.75 mM MgCl2,, 2 mM dNTP mix (0.5 mM 
each), 5 mM DTT, 1X random primers, 1.0 U /μl RNase 
inhibitor and 5.0 U/μl MultiScribe reverse transcriptase. 
10 μl of total RNAs (2 μg) were mixed well with 10 μl of 
2X master mixes. The reaction mixes were then placed in 
a thermal cycler for 10 min at 25oC, 120 min at 37oC, and 
then for 5 min at 95oC. The resulted cDNAs were diluted 
with 80 μl H2O.
End-point PCR amplification
To identify novel human fusion transcripts, specific 
primers were designed to match the 5’ and 3’ ends of a 
given fusion transcript, using a primer-designing software 
[53]. 5 μl of the cDNAs generated above were used as 
template for end-point PCR, which was carried out using 
HiFi Taq polymerase (Invitrogen, Carlsbad, CA, USA) for 
35 cycles of 94°C for 15”, 60-68°C for 15” and 68°C for 
2-5 min. The PCR products of KANSARL isoforms 1 and 2 
were separated on 2% agarose gels, recovered and cloned 
into TOPO pCR2.1 vector as suggested by manufacturer. 
After transformation and incubation at 37oC overnight, 
the plasmids with inserts were isolated and sequenced. 
The sequences were then verified by blast and manual 
inspection. For genomic fusion validation, genomic DNA 
from HeLa-3 cells was used as template for end-point 
PCR using the Phusion PCR kit (NEB), with an annealing 
temperature at 60°C.
Quantitative real-time PCR
To quantify expression levels of different KANSARL 
isoforms, isoform-specific primers were designed using 
a primer-designing software [53]. 5 μl of the cDNAs 
generated above were used as template for real-time PCR, 
which was carried out using SYBR Green PCR Master 
Mix (Roche) on a LightCycler 480II system (Roche) as 
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the manufacturer suggested. For each reaction, 5 μl of 
480 SYBR Green I Master Mix (2X), 2 μl of primers 
(10X) and 3 μl of H2O were pooled into a tube and mixed 
carefully by pipetting up and down. 15 μl of the PCR mix 
were pipetted into each well of the LightCycler® 480 
Multiwell Plate, and then mixed with 5 μl of cDNAs. The 
plate was sealed, centrifuged at 1,500 g for 2 min, and then 
transferred into the plate holder. The PCR was performed 
for 45 amplification cycles.
Further information
See Supplementary Materials and Other Supporting 
Data
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